El interés en corto de Tidal Trust II YieldMax Semiconductor Portfolio Option Income ETF da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Tidal Trust II YieldMax Semiconductor Portfolio Option Income ETF. Los datos de interés en corto se actualizan cada dos semanas.

Tidal Trust II YieldMax Semiconductor Portfolio Option Income ETF (ARCA:CHPY), Informe de interés en corto

Technology

The Fund is an actively managed exchange-traded fund (ETF) that seeks income and capital appreciation. The Funds strategy involves: (1) constructing a portfolio of U.S.-listed equity securities of Semiconductor Companies (each, an Underlying Security) (the Equity Strategy)

Broadcom Inc

Nvidia Corp.

Qualcomm Inc.

Kla Corp.

Taiwan Semiconductor Manufacturing Co Ltd

Lam Research Corp. Com New

Analog Devices Inc

Texas Instruments Inc

Monolithic Power Systems Inc

Applied Materials Inc

Microchip Technology Inc.

YieldMax Semiconductor Portfolio Option Income ETF

Small,Semiconductor,On,A,Circuit,Board.,Extreme,Closeup,Of,A

Earnings

Equities

Large Cap

News

Guidance

Dividends

Movers

CHPY

KNGZ

MCHP

Las acciones de Microchip suben un 8 % tras superar ingresos estimados, reducir inventarios y anunciar dividendo trimestral.

Microchip Technology sube en Bolsa tras superar ingresos y previsiones para el próximo trimestre

Tidal Trust II YieldMax Semiconductor Portfolio Option Income ETF

INM: 102% &#x7C; <a href="https://www.benzinga.com//node/46070476">InMed shares are trading higher after the company announced preclinical data showing INM-901 reduced neuroinflammation markers in an ex vivo Alzheimer's disease study.</a>
&nbsp;
NA: 108% &#x7C; <a href="https://www.benzinga.com//node/46070530">Nano Labs shares are trading higher after the company announced a $500 million convertible notes private placement for its BNB treasury strategy.</a>
&nbsp;
AMRN: 7% &#x7C; <a href="https://www.benzinga.com//node/46070542">Amarin shares are trading higher after the company announced an exclusive license and supply agreement with Recordati to commercialize VAZKEPA in Europe.</a>

Trading Ideas

AMRN

Market-Moving News for June 24th

WestPark Capital analyst Casey Ryan reiterates Glimpse Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAR#NASDAQ">VRAR</a>) with a Buy and maintains $2.62 price target.

Price Target

Reiteration

Analyst Ratings

VRAR

WestPark Capital Reiterates Buy on Glimpse Group, Maintains $2.62 Price Target

IRIX

Iridex-Backed DAME Trial Begins Enrollment In UK To Investigate Subthreshold MicroPulse Laser In DME Treatment Pathway

WIIM

Amarin shares are trading higher after the company announced an exclusive license and supply agreement with Recordati to commercialize VAZKEPA in Europe.

Nano Labs shares are trading higher after the company announced a $500 million convertible notes private placement for its BNB treasury strategy.

GRMN

Garmin Unveils Tacx Alpine Gradient Simulator To Deliver Realistic Indoor Cycling Experience With Climb Replication And Steering

Cheniere Approves Final Investment Decision For Corpus Christi Trains 8 & 9, Expanding LNG Capacity Beyond 60 MTPA By 2028

Microchip Enhances TrustMANAGER With FOTA And Secure Code Signing To Support EU Cyber Resilience Act And Global IoT Security Compliance

ImmunoPrecise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPA#NASDAQ">IPA</a>), a leader in AI-driven biotherapeutics, provides a significant update following its June 5, 2025, press release <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.ipatherapeutics.com%2Fnews%2Fnews-releases%2Fnews-details%2F2025%2FImmunoPrecise-Announces-AI-Driven-Breakthrough-in-Universal-Dengue-Vaccine-Discovery%2Fdefault.aspx&amp;esheet=54281308&amp;newsitemid=20250624850812&amp;lan=en-US&amp;anchor=ImmunoPrecise+Announces+AI-Driven+Breakthrough+in+Universal+Dengue+Vaccine+Discovery&amp;index=1&amp;md5=786b6aca2058f7816e5045eb326a7cd7">ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery</a>. This new release details the downstream validation of the epitope identified in that initial announcement—demonstrating that the computationally selected vaccine target is not only highly conserved across all four dengue virus types but also safe, immunologically active, and structurally stable.
"This is a major step forward," said Dr. Jennifer Bath, CEO of ImmunoPrecise. "Our AI technology not only found a new target for a universal dengue vaccine, but we've now shown it's safe and can trigger the right immune response. With this validation, we're excited to move ahead and advance this candidate toward the next stages of vaccine development."
Following the recent discovery of a unique "Achilles' heel" shared by all four types of dengue virus, ImmunoPrecise has confirmed—using its patented HYFT technology and LENSai Immunogenicity Screener—that the selected target not only remains conserved but also triggers a strong and specific immune response. This breakthrough may pave the way for a safer, more universal dengue vaccine.
The new target was discovered using the Company's proprietary LENSai platform. "Our ability to move from computational discovery to AI-guided immunogenicity validation is unique to our methodology and drug development," commented Dr. Jennifer Bath, ImmunoPrecise CEO. "Further, it ensures that our candidates are both theoretically promising and primed for real-world immune protection, a critical requirement for any viable vaccine candidate."

ImmunoPrecise Confirms AI-Discovered Dengue Vaccine Target Is Safe and Triggers Immune Response

WATT

Energous Unveils e-Sense: Battery-Free, Wireless Sensor For Real-Time Supply Chain And Temperature Monitoring

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4455394-1&amp;h=3327837114&amp;u=http%3A%2F%2Fwww.cytosorbents.com%2F&amp;a=CytoSorbents+Corporation">CytoSorbents Corporation</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that on June 18, 2025, it filed a request for supervisory review (administrative appeal) with the U.S. Food and Drug Administration (FDA) under 21 CFR 10.75, of the De Novo Denial Letter issued on April 25, 2025 for CytoSorbents' DrugSorb-ATR Device, &nbsp;(the denial letter).&nbsp; DrugSorb-ATR, which previously received Breakthrough Device Designation from the FDA, is designed to reduce the severity of bleeding in patients undergoing coronary artery bypass grafting (CABG) surgery within two days of stopping the antiplatelet drug Brilinta&#xAE; (ticagrelor, AstraZeneca), a commonly used blood thinner.
The denial letter identified remaining deficiencies that must be addressed before the De Novo Request can be granted and the device authorized for U.S. commercialization. &nbsp;In response, the Company engaged with the FDA review team to clarify and discuss the remaining deficiencies.&nbsp; After careful consultation with its regulatory counsel and advisors, the Company determined that a supervisory review through the administrative appeals process was the best path to resolve the remaining deficiencies.
The administrative appeals process allows the Company to engage with upper management of FDA's Center for Devices and Radiological Health (CDRH) in a prescribed procedure that includes a formal hearing, with a final decision typically issued approximately 60 days after the appeal is filed.
CytoSorbents' DrugSorb-ATR application with Health Canada remains under advanced review.&nbsp; As previously disclosed, Health Canada indicated that application reviews are delayed beyond their target Market Authorization Times (MAT) due to a backlog but is committed to issuing a decision at the earliest opportunity.&nbsp; The Company remains confident in receiving a final regulatory decision in 2025.

CTSO

CytoSorbents Files Request For Supervisory Review With FDA Of De Novo Denial Letter Issued For CytoSorbents' DrugSorb-ATR Device

ARRY

Array Technologies shares are trading lower after the company announced a proposed private offering of $250 million in new convertible senior notes.

Offerings

Array Technologies Announces Proposed Private Offering Of $250M New Convertible Senior Notes

CytoSorbents Initiates Formal Appeal To FDA Over DrugSorb-ATR Denial, Aiming To Address Remaining Deficiencies

ACON

Aclarion To Present At State Of Spine Surgery Think Tank In Cabo San Lucas, Showcasing AI-Powered Solutions For Chronic Low Back Pain

Ceva, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEVA#NASDAQ">CEVA</a>), the leading licensor of silicon and software IP that enables Smart Edge devices to connect, sense and infer data more reliably and efficiently, today introduced&nbsp;MotionEngine&#x2122; Hex, a next-generation motion control software solution that enables precise, natural interaction with Smart TVs and connected displays. By combining ultra-wideband (UWB) positioning with inertial measurement unit (IMU) <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4454215-1&amp;h=833481123&amp;u=https%3A%2F%2Fwww.ceva-ip.com%2Fproduct%2Fceva-motionengine%2F%3Futm_source%3DPR%26utm_medium%3Demail%26utm_campaign%3DMotionengine_Hex&amp;a=orientation+sensing">orientation sensing</a>, MotionEngine Hex delivers&nbsp;true 6-degree-of-freedom (6-DOF)&nbsp;tracking – allowing users to control on-screen content with&nbsp;touchscreen-like pointing accuracy and spatial gestures, without ever touching the screen.&nbsp;
&nbsp;
Designed for OEMs and developers seeking to push the boundaries of user interaction, <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4454215-1&amp;h=990512776&amp;u=https%3A%2F%2Fwww.ceva-ip.com%2Fproduct%2Fceva-motionengine%2F%3Futm_source%3DPR%26utm_medium%3Demail%26utm_campaign%3DMotionengine_Hex&amp;a=MotionEngine+Hex">MotionEngine Hex</a> is a robust, low-latency software stack that enables precise 3D position and orientation tracking in real time. The result is a direct, touchscreen-like experience that enhances usability and unlocks new interaction modes where the edge of the screen is no longer the limit. This direct pointing experience is ideal for navigating modern smart TV interfaces, PC monitors, commercial displays, gaming, and even controlling smart home devices.

CEVA

Ceva Unveils MotionEngine Hex to Let Control Smart TVs with Air Gestures, No Touch Needed

<ul>
<li>This study is the first human clinical trial of a manufactured organ alternative.</li>
<li>The procedure was performed on a patient experiencing liver failure who was not eligible for a liver transplant. The procedure was performed by the team at Intermountain Medical Center in Murray, Utah, led by Christopher J. Danford, MD, a transplant hepatologist at Intermountain Health.</li>
<li>Developed by Miromatrix Medical Inc., a United Therapeutics subsidiary, miroliverELAP is an external liver assist combination product consisting of a single-use MIRO-001 bioengineered liver and an extracorporeal blood circuit.</li>
<li>The bioengineered liver is made up of a decellularized porcine liver scaffold to which allogeneic3 human endothelial4 and liver cells have been added.</li>
<li>"This first of its kind treatment represents a historic achievement for United Therapeutics and Miromatrix in advancing the potential of bioengineered human organs to help save and improve patients' lives," said Jeff Ross, Ph.D.,President of Miromatrix. "We're grateful to the patient and their family, in addition to the scientists and caregivers at Intermountain Health and Intermountain Medical Center who helped make this breakthrough possible. Looking ahead, we're excited to continue progressing our ongoing phase 1 clinical trial."</li>
<li>"This groundbreaking procedure – the first of its kind in the world – represents everything Intermountain Health stands for in providing innovative, cutting-edge high-quality care for our patients," said Ralph Jean-Mary, president of Intermountain Medical Center. "We are profoundly thankful to this patient for their participation in this pioneering study, and to our exceptional Intermountain medical team, as well as our partners at United Therapeutics and Miromatrix. This procedure reinforces our unwavering commitment to leading in clinical excellence and helping people live the healthiest lives possible."</li>
<li>United Therapeutics' organ and organ alternative manufacturing efforts consist of three platforms – xenotransplantation,5 allogeneic regenerative medicine, and autologous6 regenerative medicine – encompassing four different organs: hearts, kidneys, livers, and lungs. These revolutionary programs are intended to address the ongoing shortage of transplantable organs for patients with end-stage organ disease.</li>
<li>The investigational miroliverELAP system is not approved for any use in any country.</li>
</ul>

Biotech

Health Care

General

UTHR

United Therapeutics And Intermountain Health Announced The World's First Patient Treated In A Clinical Study Of A Bioengineered External Liver Assist Product Called miroliverELAP

Financing

RPRX

Royalty Pharma Announces $2B Funding Arrangement With Revolution Medicines, Consisting Of Synthetic Royalty Up Tp $1.25B On Daraxonrasib And Senior Secured Loan Up To $750M

CLSK

CleanSpark Says It Reaches Mid-Year Target Of 50 EH/S Of Operational Hashrate

CBUS

FDA Clears Cibus And S&W Seed's Gene-Edited Altered Lignin Alfalfa For Livestock Feed, Paving Way For First U.S. Commercial Launch

Press Releases

YieldMax™ Launches Semiconductor Portfolio Option Income ETF (CHPY)

Comments

Tidal Trust II YieldMax Semiconductor Portfolio Option Income ETF

Interés en corto

Tidal Trust II YieldMax Semiconductor Portfolio Option Income ETF (ARCA:CHPY), Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL